$4.720
-0.098 (-2.07%)At close
TLS News
TLS Events
Telos Secures $34.3M Contract from Air Combat Command
Telos announced it has received a task order on a single-award, indefinite-delivery/indefinite-quantity contract from Air Combat Command's Directorate of Intelligence to modernize cybersecurity risk management across the Air Force Intelligence Community. The $34.3M task order includes a five-month base period and four one-year option periods, with room to expand and add additional task orders. If all options are exercised, the total ceiling value of the IDIQ is $37.78M. Under the contract, Telos will implement Xacta.ai across AF IC security boundaries.
Telos Reports Q2 Revenue of $47.7M, Exceeding Expectations
Reports Q2 revenue $47.7M, consensus $45.17M. The company said, "Revenue grew 33% year-over-year to $47.7 million, exceeding guidance, and driven by 44% growth in Security Solutions primarily due to the expansion of large programs in Telos ID."
Telos Awarded Contract to Support U.S. Air Force
Telos announced it has received a contract award to support the U.S. Air Force Distributed Common Ground System, the Air Force's primary intelligence, surveillance, and reconnaissance planning, collection, processing, exploitation, analysis, and dissemination system. Under the contract, Telos will provide perpetual licenses for Xacta.ai, along with support services and maintenance for its Xacta platform, including Xacta 360 and Xacta.io. The award further expands the Air Force's use of Telos' cyber governance, risk, and compliance solutions.
Sees Q2 Adjusted EBITDA of $5M-$6M
Sees Q2 adjusted EBITDA $5M-$6M. Sees Q2 adjusted EBITDA margin 11.4%-13%.
Telos Reports Q1 Revenue of $47.74M
Reports Q1 revenue $47.74M, consensus $44.62M. The company said, "Revenue grew 56% year-over-year to $47.7 million, exceeding guidance, and driven by 78% growth in Security Solutions primarily due to the expansion of large programs in Telos ID."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.



